The mechanism that has generally been accepted for the bioactivation of clopidogrel, a tetrahydrothienopyridine antithrombotic prodrug, is a two-step enzymatic conversion into a biologically active thiol metabolite. The first step is a cytochrome P450 (CYP)-dependent oxidation leading to a 2-oxo-clopidogrel thiolactone metabolite (Fig. 1) , and the second step is a CYP-dependent oxidative opening of the 2-oxoclopidogrel thiolactone ring, with the eventual formation of an active thiol metabolite [1] [2] [3] . CYP2C19 has been reported to have a key role in clopidogrel bioactivation by contributing to both steps of this bioactivation 3 , and a common genetic variant within the CYP2C19 gene, the CYP2C19*2 loss-of-function polymorphism, was found to be associated with an attenuated response to clopidogrel and a worse clinical outcome in patients undergoing coronary stenting 4 . A recent paper published in Nature Medicine 5 reported that this second step is not catalyzed by CYP enzymes, but rather depends on paraoxonase-1 (PON1), and that PON1 is a major determinant of clopidogrel efficacy. Recently, we designed experiments to understand the origin of these contradictory conclusions about the nature of the second step of clopidogrel bioactivation. As described below, we found that although both CYP enzymes and PON1 can catalyze the opening of 2-oxo-clopidogrel thiolactone, they lead to the formation of different isomers of the thiol metabolite. Moreover, the major active thiol isomer that has recently been reported to be present in the plasma of clopidogrel-treated subjects 6 is the one that our results indicate is formed via a CYP-dependent pathway.
identified at the level of their 3′-methoxyacetophenone derivatives that showed HPLC retention times and mass spectra identical to those of authentic samples of the previously described cis-thiol 3′-methoxy acetophenone derivatives 6 . Addition of 10 mM N-benzyl imidazole, a well-known inhibitor of CYP enzymes 9 , had no effects on endo-thiol formation but almost completely inhibited cis-thiol formation. These data indicate that cis-thiols are derived from a CYP-dependent pathway (as previously described by several groups [1] [2] [3] involving an oxidative opening of the thiolactone ring followed by the reduction of a sulfenic acid intermediate 2 , whereas the endo-thiol is derived from a PON-catalyzed hydrolysis (Fig. 1) . Accordingly, incubation of 2-oxo-clopidogrel with human serum, which does not contain CYP-dependent monooxygenases but in which PON1 is present, led to the formation of only the endo-thiol isomer (data not shown).
With respect to the identification of clopidogrel-derived thiol metabolites, one must note that the MS 2 spectra of the endo-and cis-isomers are different (see Supplementary Fig. 1 ). Thus, an HPLC-MS 2 analysis of mixtures of these isomers without their complete HPLC separation, which seems to be the case under the conditions used by Bouman et al. 5 , could lead to the preferential measurement of only one isomer, depending on the MS conditions used, and thus to misleading results.
We performed experiments in parallel to better understand the stereochemistry observed for 2-oxo-clopidogrel hydrolysis. Treatment of 2-oxo-clopidogrel under slightly basic conditions always led to endothiol products. For instance, its reaction with CH 3 ONa in CH 3 OH led to exclusively the endo-thiol methyl ester with good yields (>80%). These data suggest that enzymatic (PON1) and chemical hydrolysis of 2-oxoclopidogrel lead to only the endo-thiol isomer, presumably because the conjugated carbonyl function of 2-oxo-clopidogrel is not reactive enough to react with H 2 O or HO -. Accordingly, lactones are in general good substrates of PON1, but lactones involving a carbonyl group conjugated with a double bond are not substrates 8 . By contrast, the tautomer of 2-oxo-clopidogrel with the double bond having migrated within the piperidine ring, which exists in equilibrium with its major conjugated tautomer ( Fig. 1) , should be more reactive toward nucleophiles such as H 2 O or HO -. Their reaction with its carbonyl group would be predicted to lead to the observed endo-thiol isomer (Fig. 2) . Thus, the only way to form the active cis-thiol from 2-oxo-clopidogrel is to increase the electrophilicity of its carbonyl group by S-oxidation, a reaction that is catalyzed by CYP enzymes 2, 10 . Further hydrolysis of the reactive ketosulf oxide intermediate and reduction of the resulting sulfenic acid species eventually leads to the cis-thiol metabolite ( Fig. 1) 2, 10 .
The ratio of the thiol isomers in the plasma of clopidogrel-treated subjects, with the cis-thiols as major metabolites and the endo-thiol as a minor metabolite 6 , is highly similar to that which we observed after metabolism of 2-oxo-clopidogrel by NADPH-supplemented human liver microsomes (Fig. 2) . This suggests that the fate of 2-oxo-clopidogrel in vivo is also mainly dependent on CYP enzymes and only to a minor extent on esterases such as PON1. Recent data comparing the biological activity of the four cis-and trans-thiol diastereoisomers toward the platelet P2Y12 receptor showed that the most active compound is one of the cis-diastereoisomers 6 . Taking into account the thiol isomer ratios found in the plasma of clopidogrel-treated subjects, it seems that the antithrombotic activity of clopidogrel is mainly due to one of its cisthiol metabolites whose formation is dependent on CYP enzymes 1, 6 . Our results are in agreement with a recently published article showing no association of the PON1 Q192R genotype with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting 4 .
The activity of the minor endo-thiol metabolite has not yet been determined in a quantitative manner, and further experiments are required to make definitive conclusions about the relative importance of the CYP-dependent and PON1-dependent 2-oxo-clopidogrel metabolism pathways in the in vivo antiplatelet effects of clopidogrel as well as the consequences of CYP and PON1 polymorphisms for the medical use of clopidogrel. 
To the Editor:
The incidence of stent thrombosis is decreasing steadily, in part as a result of the combined treatment of patients with clopidogrel and aspirin. In a recent publication in Nature Medicine, Bouman et al. 1 demonstrated in vitro that oxidized clopidogrel is converted to the active thiol metabolite in a reaction catalyzed by PON1 (aryldialkylphosphatase, EC 3.1.8.1). Their results are plausible, as PON1 is known to catalyze the hydrolysis of thiolactones (as is oxo-clopidogrel), albeit at low rates 2 . They concluded that PON1 is a major determinant of clopidogrel efficacy. This is an important point, because it may imply that clopidogrel effectiveness depends on PON1 status. However, several aspects of the experimental procedures and data concern us and, in our opinion, merit further investigation.
First, experiments regarding PON1's activity were conducted with plasma containing EDTA (EDTA plasma). It has been known for over five decades that EDTA is an inhibitor of PON1, as the enzyme has an absolute requirement for calcium 3 . PON1 protein contains two calcium atoms, one in the active site region, required for catalytic activity, and the second required for protein stability 4 . PON1 activity is only recoverable after short periods (<1 h) of incubation with EDTA by the addition of excess calcium 5 ; longer-term incubation with EDTA results in the loss of the structural calcium and irreversible loss of activity 6 .
EDTA plasma contains an EDTA-resistant "PON1-like activity, " including lactonase activity, and this EDTA-resistant activity varies greatly between individuals 7, 8 . This activity is mainly mediated by serum albumin 9 but may also include contributions of serum hydrolases and lactonases 8 other than PON1. Adding PMSF to the buffer could have avoided interference by other lactonases 8 . Therefore, the differential therapeutic efficacy of clopidogrel could have resulted from, among other factors, differential levels of hydrolysis by albumin. Serum PON3, which, like PON1, is a lipolactonase, may also metabolize oxoclopidogrel 10 , adding a further complicating factor. Moreover, EDTAresistant activity, and the activity regained after dilution of sera in a calcium-containing buffer, is in part PON1 mediated, as PON1 attached to high-density lipoproteins is more stable to the chelator effect than is free PON1 (ref. 11). However, the R and Q isoenzymes differ in their inactivation rate by EDTA: the Q isoenzyme is inactivated ten times 
